Presentation: P03025

The cost of drug development has soared over the last decades, as well as, the efforts into sales and marketing of the end-product drugs. Companies realize that the larger they are the easier it is to bare large investments and leverage their marketing activities. In order to maximize return-on-investment, the companies are engaging in continuous merging activities.

Life Science Research companies, nowadays, consist of multiple R&D sites distributed all around the world. Individual sites often work on dedicated targets or on specific therapeutic areas with synergies generated through access to each others research results. In order to maximize global research effectiveness, all research scientists need an overview and physical access to the entire compound collection of independently built up libraries.

Close Window X